Literature DB >> 6183477

In vitro studies on the cell-mediated immune response to human brain tumors. I. Requirement for third-party stimulator lymphocytes in the induction of cell-mediated cytotoxic responses to allogeneic cultured gliomas.

M K Gately, M Glaser, S J Dick, R W Mettetal, P L Kornblith.   

Abstract

For study of those properties of human gliomas that might contribute to their ability to escape cell-mediated immune attack, cultured human glioma cells were examined for their ability to elicit allogeneic cytolytic lymphocyte responses in vitro. Of 9 glioma lines, 5 were unable to elicit allogeneic cytolytic lymphocyte responses in mixed lymphocyte--tumor cultures although the concentration of stimulating glioma cells was varied over a fortyfold range. However, lymphocytes specifically cytolytic for 4 of the nonstimulatory lines could be generated if irradiated, third-party stimulator lymphocytes were added to cultures containing responder lymphocytes and glioma cells. The specific cytolytic lymphocytes produced in these cultures were inactivated by treatment with the monoclonal anti-T-cell antibody OKT3 plus complement and were thus identified as T-cells. However, nonspecific, non-T-lytic effectors were also generated. The results of these experiments demonstrated that certain cultured gliomas possessed a defect in immunogenicity that can be overcome by "help" from an allogeneic mixed lymphocyte reaction. The possible nature of this help and the potential implications of these results for the immunotherapy of human gliomas are discussed.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6183477

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  15 in total

1.  Neurological surgery at the National Institutes of Health.

Authors:  Gautam U Mehta; John D Heiss; John K Park; Ashok R Asthagiri; Kareem A Zaghloul; Russell R Lonser
Journal:  World Neurosurg       Date:  2010-07       Impact factor: 2.104

2.  Analysis of interleukin 2 and various effector cell populations in adoptive immunotherapy of 9L rat gliosarcoma: allogeneic cytotoxic T lymphocytes prevent tumor take.

Authors:  C A Kruse; K O Lillehei; D H Mitchell; B Kleinschmidt-DeMasters; D Bellgrau
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

3.  Immunobiology of brain tumors.

Authors:  E Frank; N de Tribolet
Journal:  Neurosurg Rev       Date:  1986       Impact factor: 3.042

4.  Ultrastructural features of the lymphocyte-stimulated halos produced by human glioma-derived cells in vitro.

Authors:  M A Oberc-Greenwood; L M Muul; M K Gately; P L Kornblith; B H Smith
Journal:  J Neurooncol       Date:  1986       Impact factor: 4.130

5.  Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas.

Authors:  K B Quattrocchi; C H Miller; S Cush; S A Bernard; S T Dull; M Smith; S Gudeman; M A Varia
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

Review 6.  Microenvironmental clues for glioma immunotherapy.

Authors:  Michael Platten; Katharina Ochs; Dieter Lemke; Christiane Opitz; Wolfgang Wick
Journal:  Curr Neurol Neurosci Rep       Date:  2014-04       Impact factor: 5.081

Review 7.  Lymphokines and the brain.

Authors:  A Fontana; P J Grob
Journal:  Springer Semin Immunopathol       Date:  1984

8.  Intracranial administrations of single or multiple source allogeneic cytotoxic T lymphocytes: chronic therapy for primary brain tumors.

Authors:  C A Kruse; P M Schiltz; D Bellgrau; Q Kong; B K Kleinschmidt-DeMasters
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 9.  Immunology of gliomas.

Authors:  N de Tribolet
Journal:  Childs Nerv Syst       Date:  1989-04       Impact factor: 1.475

10.  In vitro elicitation of cytotoxic response against a nonimmunogenic murine tumor by allosensitization.

Authors:  B Leshem; B Gotsman; E Kedar
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.